The potential for the development of antidrug antibodies is a key concern among prescribers who use all biologics that target tumor necrosis factor (TNF). Two presentations at the American College of Rheumatology Annual Meeting in Chicago, Illinois, which will be held from October 19-24, 2018, will address the immunogenicity of biosimilars in patients with rheumatoid arthritis and other inflammatory diseases.
The potential for the development of antidrug antibodies (ADAs) is a key concern among prescribers who use all biologics that target tumor necrosis factor (TNF). Two presentations at the American College of Rheumatology (ACR) Annual Meeting in Chicago, Illinois, which will be held from October 19-24, 2018, will address the immunogenicity of biosimilars in patients with rheumatoid arthritis (RA) and other inflammatory diseases.
Pooled Analysis of Biosimilar Studies Show Impact of ADAs
Researchers conducted a pooled analysis of phase 3, randomized, double-blind clinical studies that compared the efficacy and safety of 3 biosimilars—SB4 (referencing etanercept), SB2 (referencing infliximab), and SB5 (referencing adalimumab)—to assess the immunogenicity of the 3 drugs and the potential impact of ADAs.1
Each of the phase 3 studies used a validated electrochemiluminescence assay to measure immunogenicity, and patients who had immunogenicity results in each study were pooled. In total, the analysis included 1710 patients.
Across treatment groups, efficacy was greater in those who did not have ADAs, and in all treatment, the rate of response as measured by the ACR criteria for a 20% improvement was reduced in the presence of ADAs (odds ratio [OR], 2.01; 95% CI, 1.60-2.53; P <.0001). The mean improvement in disease activity score in a count of 28 joints was significantly greater in patients without ADAs (estimated difference, 0.33; 95% CI, 0.19-0.48; P <.0001).
The presence of ADAs was also associated with increase injection-site reaction and infusion-related reactions (OR, 1.78; 95% CI: 1.05-3.02: = .033), especially with infliximab (OR, 2.67; 95% CI, 1.04-6.89; P = .041) versus etanercept (OR, 1.72; 95% CI, 0.38-7.77; P = .478) and adalimumab (OR ,1.14; 95% CI: 0.41-3.13; P = .804).
New NOR-SWITCH Data Show Similar Occurrence of ADAs in Originator and Biosimilar Infliximab
The NOR-SWITCH study, which has been described previously, was a 52-week study funded by the Norwegian government to assess a nonmedical switch from reference infliximab to CT-P13 in 6 indications: spondyloarthritis (SpA), RA, psoriatic arthritis (PsA), plaque psoriasis (PP), Crohn disease (CD), and ulcerative colitis (UC).
A new analysis reports on the immunogenicity of infliximab in patient treated with the reference product versus those switched to CT-P13.2
A total of 20 patients entered the study with ADAs; 9 of these patients were in the reference arm and 11 were in the biosimilar arm. An additional 36 patients—17 in the reference arm and 19 in the biosimilar arm—developed ADAs during the 52-week treatment period, and no consistent differences in ADAs were observed among diseases. No patients with plaque psoriasis developed ADAs during the study. Patients with ADAs in both arms were more likely to discontinue treatment than patients without ADAs.
All ADA-positive sera were cross-reactive with both reference and biosimilar infliximab across 5 different batches of each drug. ADAs in 60% to 79% of patients recognized 7 synthetic peptides, with no significant difference between treatment arms. Interestingly, 2 epitopes were recognized only in samples from patients with UC and CD, ad not in patients with rheumatic diseases.
The authors concluded that ADAs occurred to similar degrees in the 2 study arms, and that most patients had no consistent difference in epitope specificity. However, research into the 2 epitopes recognized by patients with UC and CD is ongoing.
References
1. Emery P, Weinblatt ME, Smolen JS, et al. Impact of immunogenicity on clinical efficacy and administration related reaction in TNF inhibitors: a pooled analysis from three biosimilar studies in patients with rheumatoid arthritis. Presented at the American College of Rheumatology 2018 meeting, October 19-24, 2018; Chicago, Illinois. Abstract 1532. https://acrabstracts.org/abstract/impact-of-immunogenicity-on-clinical-efficacy-and-administration-related-reaction-in-tnf-inhibitors-a-pooled-analysis-from-three-biosimilar-studies-in-patients-with-rheumatoid-arthritis/.
2. Goll GL, Bolstad N, Iria I, et al. Immunogenicity of originator and biosimilar infliximab: anti-drug antibody occurrence, cross-reactivity and epitope specificities across six diseases. Analysis from a Norwegian randomized switching trial. Presented at the American College of Rheumatology 2018 meeting, October 19-24, 2018; Chicago, Illinois. Abstract 700. https://acrabstracts.org/abstract/immunogenicity-of-originator-and-biosimilar-infliximab-anti-drug-antibody-occurence-cross-reactivity-and-epitope-specificities-across-six-diseases-analyses-from-a-norwegian-randomized-switching-tri/.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.